Epiq Capital Group, LLC Cyclo Therapeutics, Inc. Transaction History
Epiq Capital Group, LLC
- $269 Million
- Q2 2024
A detailed history of Epiq Capital Group, LLC transactions in Cyclo Therapeutics, Inc. stock. As of the latest transaction made, Epiq Capital Group, LLC holds 817,270 shares of CYTH stock, worth $645,643. This represents 0.39% of its overall portfolio holdings.
Number of Shares
817,270
Previous 853,815
4.28%
Holding current value
$645,643
Previous $1.19 Million
12.56%
% of portfolio
0.39%
Previous 0.47%
Shares
2 transactions
Others Institutions Holding CYTH
# of Institutions
23Shares Held
2.24MCall Options Held
0Put Options Held
0-
Founders Fund V Management, LLC San Francisco, CA481KShares$379,75972.16% of portfolio
-
Vanguard Group Inc Valley Forge, PA447KShares$352,7920.0% of portfolio
-
Geode Capital Management, LLC Boston, MA175KShares$138,5800.0% of portfolio
-
Founders Fund Vi Management, LLC San Francisco, CA110KShares$86,918100.0% of portfolio
-
Black Rock Inc. New York, NY59.5KShares$47,0120.0% of portfolio
About Cyclo Therapeutics, Inc.
- Ticker CYTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 8,439,440
- Market Cap $6.67M
- Description
- Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of...